[Experimental testing of a new gastrotherapeutic agent].
A new gastrotherapeutical preparation, AcT 72, has been evaluated. This preparation contains the anticholinergic drug propantheline bromide, the psychotherapeutical agent perazine, and antacids. In two different series of tests it was demonstrated that after a peroral dose of ACT72, gastric motility was significantly reduced when compared with the control situation. Dosages used were in accordance with normal therapeutic doses, and, because of the influence on gastric motility, the duration of action in the stomach was prolonged, thus reducing daily dose requirements. Reduction of stomach motility per se, has therapeutic value in patients with gastric ulcers.
D000328:Adult; D000863:Antacids / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D008297:Male; D010464:Perazine / Q000627:therapeutic use*; D011413:Propantheline / Q000627:therapeutic use*; D013276:Stomach Ulcer / Q000188:drug therapy*
D000863:Antacids; D014150:Antipsychotic Agents; D004338:Drug Combinations; D011413:Propantheline; D010464:Perazine
Experimentelle Prüfung eines neueren Gastrotherapeutikums